Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01400-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Eman G Youssef und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Cen…. Hauptthemen laut MEDLINE: Antifungal Agents, Polyenes, Aspergillus, Invasive Pulmonary Aspergillosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Elion Therapeutics.
Abstract (Originalsprache)
Invasive pulmonary aspergillosis (IPA), mainly caused by A. fumigatus, remains a life-threatening fungal infection, with rising reports of infections caused by resistant species such as Aspergillus lentulus and Aspergillus calidoustus . EL219 (formerly known as SF001) is a novel, next-generation polyene with enhanced ergosterol selectivity and reduced nephrotoxicity. We evaluated the efficacy of EL219 compared to liposomal amphotericin B (LAMB) in vitro using the Clinical Laboratory and Standards Institute M38 methodology and in immunosuppressed murine models of IPA caused by A. fumigatus , A. lentulus , and A. calidoustus . Immunosuppressed ICR mice were infected via inhalation ( A. fumigatus ) or via intratracheal instillation ( A. lentulus and A. calidoustus ), then treated intravenously once daily with placebo, EL219 (0.3, 1.5, 7.5, and 30 mg/kg), or LAMB (5 mg/kg) starting 16 h post-infection. Treatment lasted 4 days ( A. fumigatus and A. lentulus ) or 7 days ( A. calidoustus ). Survival through Day 21 and lung fungal burden at Day 4 were assessed. EL219 showed enhanced in vitro activity against A. lentulus and A. calidoustus compared to LAMB. EL219 significantly improved survival in a dose-dependent manner, with 30 mg/kg outperforming LAMB. EL219 also resulted in >5-log fungal burden reductions in A. fumigatus -infected lungs. EL219 demonstrated broad-spectrum efficacy, improved survival, and reduced lung fungal burden, supporting its potential as a novel therapy for IPA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
ORCID-Profile: Eman G Youssef, Teclegiorgis Gebremariam, Yiyou Gu, Nathan P Wiederhold, Ashraf S Ibrahim
Förderung
- NIAID NIH HHS
- Elion Therapeutics
Zitieren
APA
Youssef, E. G., Gebremariam, T., Gu, Y., Patterson, H., Alkhazraji, S., Elsayed, T., Wiederhold, N. P., & Ibrahim, A. S. (2026). Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01400-25
Vancouver
Youssef EG, Gebremariam T, Gu Y, Patterson H, Alkhazraji S, Elsayed T, et al. Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01400-25
BibTeX
@article{Youssef2026,
author = {Youssef, Eman G and Gebremariam, Teclegiorgis and Gu, Yiyou and Patterson, Hoja and Alkhazraji, Sondus and Elsayed, Tasneem and Wiederhold, Nathan P and Ibrahim, Ashraf S},
title = {Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01400-25}
}
EUVIMED